Said Alnajjar
Papers
1
Total Citations
2
H-Index
1
About
Dr. Said Alnajjar is a clinical researcher whose work centers on improving outcomes in colorectal cancer (CRC), with a particular focus on the critical window between surgical resection and adjuvant chemotherapy (AC). His major contribution lies in identifying the predictors that influence both the timely initiation and successful completion of AC in patients with stage II/III colorectal adenocarcinoma. By analyzing real-world clinical data, Dr. Alnajjar’s research provides actionable insights into the patient, disease, and system-level factors—such as postoperative complications, hospital volume, and socioeconomic barriers—that can delay or derail this life-saving treatment. His work directly supports the clinical imperative, backed by multiple trials, that AC should begin within 6-8 weeks of surgery to maximize survival benefits. With his most cited paper from 2024 already garnering attention, Dr. Alnajjar is establishing himself as a key voice in evidence-based oncology, bridging the gap between clinical trial recommendations and everyday practice to ensure more patients receive timely, complete cancer care.
Research Focus
Key Achievements
Top Papers
- 1